Analyst Price Targets — ANNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 20, 2026 10:50 am | Andrew Fein | H.C. Wainwright | $14.00 | $5.80 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX) |
| May 12, 2026 9:12 am | — | Goldman Sachs | $7.00 | $5.68 | TheFly | Annexon initiated with a Neutral at Goldman Sachs |
| December 23, 2025 9:30 am | Daniil Gataulin | Chardan Capital | $16.00 | $5.19 | TheFly | Annexon initiated with a Buy at Chardan |
| June 5, 2024 5:54 am | Derek Archila | Wells Fargo | $14.00 | $5.99 | StreetInsider | Annexon Biosciences (ANNX) PT Raised to $14 at Wells Fargo |
| May 15, 2024 5:14 am | Derek Archila | Wells Fargo | $10.00 | $4.82 | StreetInsider | Annexon Biosciences (ANNX) PT Lowered to $10 at Wells Fargo |
| April 1, 2024 5:50 am | Derek Archila | Wells Fargo | $12.00 | $7.17 | StreetInsider | Wells Fargo Adds Annexon Biosciences (ANNX) to Q2 '24 Tactical Idea List |
Latest News for ANNX
BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity…
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label.
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANNX.
U.S. House Trading
No House trades found for ANNX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.